Desimplification to multi-tablet antiretroviral regimens in human immunodeficiency virus-type 1 infected adults: A cohort study

Table 3 Before-after (week 24 vs week 48/week 96) analysis of plasma viremia (4 levels and dichotomized)

	Crosstabulation (Week 48 vs week 24)						Crosstabulation (Week 96 vs week 24)						Pooled data
FDC
HIV-RNA (copies/mL)	NR	< 20	20-50	> 50	Discontinued study drug	Total	NR	< 20	20-50	> 50	Discontinued study drug	Total	3P = 0.972; GOR 1.00 (95%CI: 0.66 to 2.06)
NR	43	11	3	0	3	60	42	10	3	0	5	60
< 20	7	0	1	1	1	10	5	4	0	0	1	10
20-50	5	2	1	0	0	8	4	2	1	0	1	8
> 50	1	1	0	0	0	2	2	0	0	0	0	2
Total	56	14	5	1	4	80	53	16	4	0	7	80
	P = 0.8601; GOR = 1.00 (95%CI: 0.50 to 2.00)						P = 0.8451; GOR = 1.00 (95%CI: 0.46 to 2.16)
HIV-RNA (copies/mL)	≥ 20	< 20	Total					≥ 20	< 20	Total	(I-squared = 0.0%); 2P = 0.072; Odds ratio (odds A: odds B) = 0.471; Fisher’s 95%CI: 0.176 to 1.151
≥ 20	1	9	10					1	8	9
< 20	5	61	66					3	61	64
Total	6	70	76					4	69	73
	2P = 0.285						2P = 0.132
MTR
HIV-RNA (copies/mL)	NR	< 20	20-50	> 50	Discontinued study drug	Total	NR	< 20	20-50	> 50	Discontinued study drug	Total	3P = 0.036; GOR 1.65 (95%CI: 0.97 to 5.52)
NR	77	16	1	0	10	104	71	12	1	0	20	104
< 20	17	6	2	0	9	34	16	5	1	0	12	34
20-50	4	6	3	1	1	15	4	4	1	0	6	15
> 50	2	1	0	0	2	5	1	0	1	0	3	5
Discontinued study drug	0	0	1	0	4	5	0	0	0	0	5	5
Total	100	29	7	1	26	163	92	21	4	0	46	163
	P = 0.2031; GOR = 1.50 (95%CI: 0.85 to 2.64)						P = 0.0821; GOR = 1.86 (95%CI: 0.97 to 3.56)
HIV-RNA (copies/mL)	≥ 20	< 20	Total					≥ 20	< 20	Total	(I-squared = 0.0%); 2P = 0.001; Odds ratio (odds A: odds B) = 0.227; Fisher’s 95%CI: 0.067 to 0.615
≥ 20	4	13	17					2	9	11
< 20	3	116	119					2	104	106
Total	7	129	136					4	113	117
	2P = 0.012						2P = 0.035

¹McNemar test with continuity correction;

²McNemar test (two-tailed);

³Combination of the Mann-Whitney paired-data tests (weighting by sample sizes). I-squared: Higgins and Thompson’s heterogeneity test; GOR: Generalized odds ratio; HIV: Human immunodeficiency virus; MTR: Multi-tablet regimen; FDC: Fixed dose coformulation.